搜索到 1000 条关于 수입산미국시알리스 복제약 구매 K444.top 정품수입산미국시알리스 해외직구 정품미국비아그라 복용법 정품수입산미국프릴리지 약국 ioB 的文章
-
2012.09.19 2010 第五届国际基因组学大会(ICG-V)
, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster
-
2012.09.19 2012 中国医疗器械高峰论坛
trials and regulatory affairs A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China
-
2013.10.22 弥漫性白质脑病伴囊性变的Wilson病一例
患者,男,16岁,进行性构音障碍、步态及行为异常。基于双眼K-F环,低血铜,低铜蓝蛋白和24小时尿铜增加,初步诊断为肝豆状核变性(Wilson病),且最终通过分子分析确认([Glu1382*]纯合子)。颅脑MRI显示弥漫性双侧皮质及皮质下异常。驱铜治疗后(D青霉胺)尽管患者发展为癫痫样抽搐(可能为皮质受侵入),但局部功能改善。伴广泛皮质及皮质下病灶的肝豆状核变性很罕见,但是当出现弥漫性白质脑病伴囊性变时还是需要考虑肝豆状核变性。查看更多
-
2012.09.19 国际植物药研究与开发论坛暨2009年新疆药学年会
新疆药学会定于2009年7月15日在自治区科技馆召开国际植物药研究与开发论坛暨2009年新疆药学年会,同时举行新疆药学科技奖颁奖仪式。现将现将相关事宜通知如下:征文范围及要求:会议内容本次国际论坛会议邀请了以下专家:法国专家: 姓 名 工作单位① C. CIRARD教授 Universite de Franche-Comte授课内容:生药学② C. DEMOUGEOT教授 Universite de Franche-Comte授课内容:药理学③ D. VUITTON教授 Universite de Franche-Comte授课内容:药物研究方法学④ F. MUYARD教授 Universite de Franche-Comte授课内容:法国药学分子系统泰国专家: 姓 名 工作单位① K. CHOOTIP教授 Naresuan University授课内容:药剂学② D. PEKTHONG教授 Naresuan University授课内容:泰国药学分子系统
-
2012.09.19 第二届全球华人消化内镜学术大会
自从“第一届全球华人消化内镜学术大会”成功举办之后,四年过去了,消化内镜技术又有了飞速的发展,如NOTES、NBI、EUS、ESD等。为了进一步推进和提高我国消化内镜技术的发展,也为了展示全球华人消化内镜专家在该领域的成就,促进全球华人在该领域的学术交流,由中华医学会消化内镜学分会主办、第二军医大学承办的“第二届全球华人消化内镜学术大会”定于2009年9月10~13日在上海国际会议中心举办。届时世界著名的华人消化内镜专家,如曹世植(William Chao)、蓝庆民(Nib Soehendra)、钟尚志(Syndey Chong)、梁永昌(Joseph Leung)、沈祖尧(Joseph J.Y. Sung)、陈仰光(Yang K.Chen) 等就消化内镜的最新进展作精彩的专题学术报告,并作消化内镜最新技术的现场演示。同时,此次会议还增设了腹腔镜专场和现场手术演示。大会组委会热情欢迎各位同道参加此次盛会,共同促进我国消化内镜事业的不断发展和加强华人间和国际的学术交流。参加本次会
-
2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)
时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd会议简介
According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.
Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..
IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.
5 Reasons To Attend - Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
- Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
- The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
- Showcasing unique case studies from leading Asian and international biosimilar companies
- Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success
Industry Gurus / Speakers Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals Past Attendees Include Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)Registration FEES per delegate Early Bird Rate
Register & Pay before 11 March 2011Special Rate
Register & Pay before 15 April 2011Normal Rate
Register & Pay after 15 April 2011Group Rate
Group of 3 or more? US$ / CNYUS$ / CNYUS$ / CNYUS$ / CNY4 day package
(Conf + Pre & Post Workshops)2,495 /
16,6002,695 /
17,9502,895 /
19,5002,175 /
14,6503.5 day package (Conf + Workshop C & A or B ) 2,295 /
15,5002,495 /
16,6002,695 /
17,9502,025 /
13,5003 day package (Conf + Workshop A & B or C) 1,995 /
13,5002,195 /
14,6002,395 /
15,9501,795 /
12,0002.5 day package (Conf + Workshop A or B) 1,795 /
12,0001,995 /
13,5002,195 /
14,6001,695 /
10,9502 day package
(Conf only)1,495 /
9,9501,695 /
11,3001,895 /
12,6001,495 /
9,950PAYMENT TERMS
Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.Payments by Singapore Dollars (S$)
Payments by RMB (CNY)- Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
- Payment by telegraphic transfer in S$ must be made to:
IBC Asia (S) Pte Ltd
A/C No.: 147-059513-001 (SGD)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building, Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232 - Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
- Payment by telegraphic transfer in CNY must be made to:
A/C Name:
A/C No.: 720-031103-001
Beneficiary Bank:
Bank Address: No. 1000 Lujiazui Rind Road,
Pudong, Shanghai 200120, P.R. China
Bank Swift Code: HSBCCNSH
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.
Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.
DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.联系方式电话:+65 650 82401
-
2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班(8.20-22)
。【报名回执】访问此链接填写报名回执(https://www.wjx.top/jq/80710449.aspx)【咨询请联系】QQ 号:2814500767邮箱
-
2018.09.14 WHAT?降压药还能用来治疤痕?
」、「雷米普利」、「氯沙坦」、「肼苯哒嗪」(非 ACE 类降压药)和「空白组」。C) 术后 14 天时的疤痕情况,「K」、「R」、「L」、「H」和「B」 依次为「ACE...疤痕大体情况。C) 术后 16 天小鼠疤痕的组织学切片(HE 染色)。K,KO to C57:ACE 基因敲除小鼠的骨髓移植到普通小鼠;10,ACE 10
-
2017.09.21 累及双侧丘脑的 15 种疾病,你遇到过几个?
上很难进行区分定性,今天我们就双侧丘脑病变的相关内容进行讨论,希望对大家临床工作有所帮助。1. 血管疾病1.1 基底动脉尖综合征(Top of basilar...,血清铜蓝蛋白降低,导致肝、脑、肾、角膜等部位异常铜沉积。典型临床症状表现为「三联征」:肝硬化、角膜「K-F 环」和基底节变性。主要累及壳核、桥脑、基底节、丘脑
-
2017.08.13 卒中后抗血小板出血风险有多大?有这10个特征需谨慎
)(即 S2TOP-BLEED 评分模型,见表1)。表 1 预测严重出血的S2TOP-BLEED 评分(来自多变量 Cox 回归模型)具体评分方法为,根据患者临床特征评估 S2TOP-BLEED 评分列表中每一栏分值,除了年龄相关的项目外,将其他所有项目分值想加得总分,再将总分代入图 1 所示风险分布图中,得到不同
-
2014.12.23 远程协作治疗创伤后应激障碍
明,使用远程医疗工具,如电话,互动视频和共享电子病历进行的多学科PTSD非现场干预,即创伤后应激障碍远程医疗服务(TOP)与常规护理(UC)相比,治疗效果显著提升...包括了2009年11月至2011年9月份在CBOCs接受治疗的265名主要生活在农村的退伍军人。所有患者均符合PTSD诊断标准,他们被随机分配接受TOP治疗(N
-
2020.12.23 干货 | 一文掌握妊娠期剧吐的处理要点!
;vomiting of pregnancy and hyperemesis gravidarum (green top guideline 69).22 Jun 2016[4] 谢幸, 孔北华, 段涛. 妇产科学(第 9 版)[M]. 人民卫生出版社: 北京,2018:82.[5]Källén B,Use
-
2020.02.19 当心抗病毒神药被滥用
].Transpl Infect Dis, 2016, 18(4):634- 636.[11] Shook B C, Lin K..Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus.[J].Top Curr Chem
-
2020.02.13 儿科医生当心,抗病毒「神药」4 种常见不规范使用
K..Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus.[J].Top Curr Chem (Z), 2017, 375(2):40.[12] Glue P.The clinical pharmacology
-
2019.11.21 妊娠剧吐,这有一份治疗说明书给你!
of nausea and vomiting of pregnancy and hyperemesis gravidarum (green top guideline 69).22 Jun 2016[4] 谢幸, 孔北华, 段涛. 妇产科学(第 9 版)[M]. 人民卫生出版社: 北京,2018:82.[5]Käll
-
2016.06.08 第一届阜外国际复杂先心病高峰论坛
in America2014Delaware Today magazine, Top Doctors2013Best Doctors in America美国威尔明顿市阿...), FRCSEd, FCSHK, FHKAM(Surgery)香港皇家玛丽医院胸心外科主管和高级顾问。10.K.S. MurthyChief Pediatric
-
2017.07.27 VTE 患者隐源性肿瘤风险评分有助识别肿瘤高风险患者
符合入选标准,444 例被确诊为隐源性肿瘤。以男性,年龄>70 岁,慢性肺疾病、贫血、血小板计数升高 (≧350000x1000/mm3),既往 VTE
-
2012.10.15 Qualitest公司召回氨酚氢可酮
了C1440512A批号的药品消费者应打1-800-444-4011联系Qualitest公司。消费者如果不能确定是否购买使用过该批次 的药品,应咨询药店或保健专业人员。药剂师
-
2012.10.15 Qualitest公司召回氨酚氢可酮
了C1440512A批号的药品消费者应打1-800-444-4011联系Qualitest公司。消费者如果不能确定是否购买使用过该批次 的药品,应咨询药店或保健专业人员。药剂师